SPRY Earnings Date: Nov 5, 2026 (Estimated) — ARS Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is SPRY's next earnings date?
ARS Pharmaceuticals, Inc. (SPRY) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.34 on revenue of $42.0M.
How did SPRY do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), ARS Pharmaceuticals, Inc. posted EPS of -$0.63 versus the -$0.48 estimate, a miss of 26.0%. Revenue was $33.7M against a $31.3M estimate. The stock's 1-day post-earnings move was -7.4%.
How much does SPRY stock move after earnings?
SPRY beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 8.3% (up or down) in the day after earnings.
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.48 | -0.63 | -26.00% | $33.7M | ❌ Miss | -7.38% | -9.75% | -26.23% |
| 2026-05-15 | Q1 2026 | -0.53 | -0.61 | -15.09% | $22.7M | ❌ Miss | -6.49% | +3.65% | +23.55% |
| 2026-03-09 | Q4 2025 | -0.46 | -0.42 | +8.70% | $28.1M | ✅ Beat | -0.11% | -7.40% | -10.04% |
| 2025-11-10 | Q3 2025 | -0.47 | -0.52 | -10.64% | $32.5M | ❌ Miss | +0.34% | -7.23% | +12.20% |
| 2025-08-13 | Q2 2025 | -0.47 | -0.46 | +2.13% | $15.7M | ✅ Beat | -5.04% | -17.23% | -39.08% |
| 2025-05-14 | Q1 2025 | -0.36 | -0.35 | +2.78% | $8.0M | ✅ Beat | -9.36% | +7.34% | +7.87% |
| 2025-03-20 | Q4 2024 | -0.12 | 0.48 | +500.00% | $86.6M | ✅ Beat | +22.83% | +8.15% | +27.73% |
| 2024-11-13 | Q3 2024 | -0.15 | -0.20 | -33.33% | $2.1M | ❌ Miss | -15.23% | -16.98% | -23.90% |
Showing last 8 quarters.
Revenue by segment & region
By region
Q2 FY26 · $39.4M total
| Segment | Share | Revenue | YoY | Q2 FY26 |
|---|---|---|---|---|
| UNITED STATES | 66.5% | $26.2M | — | $26.2M |
| DENMARK | 14.6% | $5.8M | — | $5.8M |
| Non-US | 10.4% | $4.1M | — | $4.1M |
| JAPAN | 8.5% | $3.4M | — | $3.4M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.